In one paragraphArticle in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
16 authors.
Tuulia ValliusLaboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115.ORCID 0000-0002-3006-4887 Yingxiao ShiLaboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115.ORCID 0000-0003-2783-9642 Edward NovikovLaboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115.ORCID 0000-0003-1476-5111 Shishir M PantLaboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115.ORCID 0000-0002-2686-7898 Roxanne PelletierLaboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115.ORCID 0000-0002-1957-5483 Yu-An ChenLaboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115.ORCID 0000-0001-7228-4696 Juliann B TefftLaboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115.ORCID 0000-0002-8826-665X Ajit Nirmal JohnsonLaboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115.ORCID 0000-0003-4139-0618 Zoltan MaligaLaboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115.ORCID 0000-0003-4209-7253 Guihong WanLaboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115.ORCID 0000-0003-1100-4018 George MurphyProgram in Dermatopathology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115.ORCID 0000-0001-9362-5146 Sandro SantagataLaboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115.ORCID 0000-0002-7528-9668 Yevgeniy R SemenovLaboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115.ORCID 0000-0002-7387-3094 David LiuDepartment of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215.ORCID 0000-0003-0346-5033 Christine G LianProgram in Dermatopathology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115.ORCID 0000-0003-4626-1612 Peter K SorgerLaboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115.ORCID 0000-0002-3364-1838 Funding
VectorP30CA006516 · NCI · DANA-FARBER CANCER INSTITUTE · PI Irene M. Ghobrial · 1985 to 2026
$330.6MPre-cancer atlases of cutaneous and hematologic origin (PATCH Center)U2CCA233262 · NCI · HARVARD MEDICAL SCHOOL · PI SANTAGATA, SANDRO · 2018 to 2023
$8.7MHigh dimensional digital pathology to investigate the tumor micro environment and its impact on response to therapyR50CA252138 · NCI · HARVARD MEDICAL SCHOOL · PI MALIGA, ZOLTAN · 2020 to 2024
$1.0MIntegrative Prediction of Therapeutic Response in T-cell Lymphoma by Omic and Spatial ModelingR00CA256497 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI NIRMAL, AJIT JOHNSON · 2023 to 2025
$747kNCI NIH HHS P30 CA006516NCI NIH HHS R00 CA256497NCI NIH HHS R50 CA252138NCI NIH HHS U2C CA233262
6 · The paper itselfAbstract
Early detection of melanoma through skin surveillance is critical for preventing metastatic progression. Primary cutaneous melanomas at early stage offer a unique opportunity to uncover fundamental mechanisms of tumor initiation, progression, and immune surveillance, but detailed spatial profiling of early disease remains limited. Here we integrate high-plex cyclic immunofluorescence (CyCIF) imaging, spatial transcriptomics, and conventional histology to identify factors associated with de-differentiation and dermal invasion in early-stage melanomas. We demonstrate a high level of variability from one primary cancer to the next, from one 100-300 cell microregion to the next within a single cancer, and from one cell to the next within a microregion. Intra-tumoral heterogeneity is influenced by local features of the microenvironment including proximity to T and myeloid cells and to perivascular environments. Thus, tumor plasticity and spatial heterogeneity arise early in melanoma development, potentially allowing for competition among multiple tumor states during the emergence of invasive disease.
Indexed as
cancer progressioncell state switchCutaneous melanomadedifferentiationintratumor heterogeneitylineage plasticitymelanoma heterogeneitymultiplex imagingspatial transcriptomicsspatial variance
Identifiers
PMID40667360
PMCPMC12262277
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390